Maximising Pharma Patents 2013

Key Topics

• Why will London be important for Pharma and biotech patents? What strategies should be considered during the transition to the new system?
• The risks, challenges and opportunities of the proposed unitary patent. How the proposed unitary patent compares with the current European patent. Where and how you will be able to sue for infringement or challenge validity in Europe, in terms of what judges, what languages, and what type of procedure will be involved?
• Employing recent cases on SPCs in Europe and the US to file successful applications
• Scope of SPCs for combination products and the cases referred to the ECJ
• Guidance from the EU Commission on lifecycle extensions
• Examining potential anti-competitive practices and recent patent settlement agreements